Completed Enrollment

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

I9Y-OX-JDHB -

The main purpose of this study is to learn more about the safety, side effects, and early effectiveness of LY3410738. LY3410738 may be used to treat blood cancers that have a change in a particular gene (known as the IDH gene).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Leukemia - AML, Leukemia - CML, Myelodysplastic Syndrome
What the trial is testing?
LY3410738
Could I receive a Placebo?
No
Enrollment Goal
260
Trial Dates
Dec 1, 2020 - May 2024
How long will I be in the trial?
Participation could last up to 2.5 years and possibly longer if the disease does not get worse.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have advanced blood cancer with a change in the IDH1 or IDH2 gene

  • Have already had treatment

  • Be well enough to perform their own personal care

  • Have adequate organ function and blood counts, as measured by blood tests

  • Have stopped all cancer treatment and have recovered from the major side effects

Participants Must Not:

  • Have an active infection
  • Have cancer that has spread to the brain or spinal cord and is causing symptoms
  • Have any problems absorbing food or medicine taken by mouth
  • Be taking certain medicines that affect how fast the study drug is broken down in the body
  • Be pregnant or breast-feeding during the study or within 90 days after the last dose of study drug

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources